Currently, there is a lack of unified standards for treatment of Branch atheromatous disease (BAD).,This study aimed to investigate the optimal antiplatelet therapy with BAD from Minor Ischemic Stroke or Transient Ischemic Attack,: Analyses from the CHANCE and CHANCE-2 Trial

BAD patients who were in CYP2C19 Loss-of-Function Carriers s (poor or intermediate metabolizers) were stratified by three groups ( ticagrelor-aspirin ,clopidogrel-aspirin and asprin alone) ,The primary efficacy outcome was the proportion of good prognosis. (MRS 0-1 or 0-2) among three treatments(ticagrelor-aspirin ,clopidogrel-aspirin and asprin alone) in 90days The second outcome was new strokes within 90days.

CHANCE and CHANCE-2 Trial, BAD patients